Innate Pharma is an immunology biopharmaceutical company developing first-in-class drugs, primarily for cancer indications.
The Company develops two categories of immunotherapies: immuno-modulators* and cytotoxic antibodies**: seven proprietary programs, of which two are tested in clinics. Two other are out-licensed to the Danish company Novo Nordisk A/S.
These therapeutic approaches could have an application in several therapeutic areas such as cancer, inflammation or infectious diseases.  

Founded in 1999, the Company was first listed on NYSE-Euronext Paris in 2006. It is based in Marseilles, France, and had 86 employees as at June 30, 2009.

 *   modulating the activity of specific immune cell populations which in return directly kill   tumoral or infected cells and trigger a global immune reaction

** directly targeting receptors expressed on tumoral cells and triggering their destruction